VSIR and neoplasm: This change indicates that VISTA mAb therapy may hinder the infiltration of immature myeloid progenitor cells, which may differentiate into MDSCs at the tumor site, to impair the recruitment of M-MDSCs into tumor issues, impairing the suppressive cellular signature of the TME [87].